Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid-Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis.

Lipids - 1 May 2026

Zhao Chao, Wang Nuan, Shi Di, Zhou Hao, Chen Dan, Chen Guofang

Abstract excerpt

Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid-lowering therapy, potentially influenced by genetic variations, particularly in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cholesterol, LDL
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Intracranial Arteriosclerosis

Share to Lipids

Share to Proprotein Convertase 9

Share to Treatment Outcome

Source

Identifiers

PMID: 41423442
DOI: 10.1002/lipd.70018

Genes

CYP2C19
PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid-Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis.PMID 41423442Read ↗

The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

PCSK9 gene Polymorphism and Assessment of Cardiovascular Risk and Prognosis in Patients With Hyperlipidemia: A Retrospective Cohort Study.Semantic proximity Read ↗

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity Read ↗

Genetic Regulation of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes.Semantic proximity Read ↗

Impact of Cytochrome P450 2C19 Polymorphism on Ischemic Stroke PrognosisSemantic proximity Read ↗

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.Semantic proximity Read ↗

Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.Semantic proximity Read ↗

Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic StrokeSemantic proximity Read ↗

Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies.Semantic proximity Read ↗

Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.Semantic proximity Read ↗

Lipid Metabolism Genes in Stroke Pathogenesis: The AtherosclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.